KINETO Lab receives a grant in the frame of BIOSMALL Consortium

16/06/2023 Grants KINETO Lab receives a grant in the frame of BIOSMALL Consortium The research proposal aims to deepen our understanding of the biological and clinical significance of molecular subtypes in small cell lung cancer (SCLC). Furthermore, our project might represent a step forward in the development of subtype-specific therapeutic approaches and follow-up strategies in this devastating disease. Specifically, our results might help to elucidate the proteomic significance of SCLC subtypes and also to identify novel potentially targetable proteins and proteomic pathways. Second, the specific features of each molecular subtype will be also determined in our study by performing genetic mutation analysis and using in-depth machine-learning algorithms. Third, our in vitro and in vivo results might reveal the biological efficacy of several chemotherapeutic and targeted agents (alone and in combinations as well), thus contributing to the development of new therapeutic approaches. Fourth, our in vivo metastatic models allow us to gain insights into the specific metastatic patterns of each subtype, which may ultimately lead to novel subtype-specific screening and follow-up strategies. Fifth, the results of the immunohistochemistry analyses of the human tissue specimens, and the findings of radiomics will eventually clarify the clinicopathological, predictive and prognostic relevance of molecular subtypes in SCLC patients. Lastly, by collecting and analysing the blood samples of SCLC patients, our project might represent a step forward in the development of subtype-oriented liquid biopsies. These objectives are measurable, verifiable and realistically achievable. Altogether, by shedding light on the biological and clinical relevance of SCLC subtypes, the current study might help to improve patient selection and develop novel therapeutic strategies. The consortium agreement is now being signed and the new project will start on 1st of October. PreviousNext

KINETO Lab receives European Union research grant for the HORIZON-HLTH — Next Generation Vaccine — NEXGEN-PD project

13/12/2022 Grants KINETO Lab receives European Union research grant for the HORIZON-HLTH — Next Generation Vaccine — NEXGEN-PD project Parkinson’s Disease (PD) is a major neurodegenerative disorder with no established treatment modalities capable of modifying disease pathology, and no means of early diagnosis. Vaccines targeting aSyn aggregates are a promising route to disease-modifying therapy for PD, but the current generation of PD vaccines utilise conventional formulations, which are limited in their immunogenicity and require substantial quantities of adjuvant to achieve efficacy. NEXGEN’s proprietary WISIT vaccine platform is the first of the novel class of gluconeoconjugate vaccines (GNCVs), which are administered intradermally and specifically formulated to leverage skin dendritic cells (DCs) to generate substantially stronger and more specific immune responses than conventional vaccines. These stronger immune responses allow substantial reduction in adjuvants, while simultaneously increasing therapy efficacy. NEXGEN will identify and characterise candidate WISIT constructs targeting aSyn (PD-WISITs) and develop a novel extracellular vesicle (EV)-based biomarker assay that enables early diagnosis of PD using liquid biopsies, suitable for point of care use. Safety and efficacy of PDWISITs will be demonstrated preclinically, before being translated to first-in-human Phase I/Ib clinical trials, along with the novel EVbased biomarker assay. The results of NEXGEN will be the extraordinary accomplishments of cheap and effective disease-modifying treatment of early PD and a novel biomarker assay to diagnose and guide prodromal/early PD treatment. Further still, GNCV technology will be clinically demonstrated, which has the potential to be transformative to the treatment of a wide range of additional diseases, resulting in far-reaching impacts to the health of millions. Duration in months: 48 The grant contract is being signed. More about the consortium you can find on this link. PreviousNext

KINETO Lab receives Hungarian research grant FUTURE-2021 for the KRAS project

08/01/2021 Grants KINETO Lab receives Hungarian research grant FUTURE-2021 for the KRAS project KINETO Lab is a member of the RASopathies network, which was launched by in 2016, for development of diagnosis and targeted therapy of rasopathies. Continuation of this project for development of KRas targeting small molecules, inhibiting tumor cells carrying different KRas mutations (G12C, D, V) on in vitro and in vivo tumor models is supported until 2024. PreviousNext

Received European Union research grant for the ETN MAGICBULLET::RELOADED project

12/05/2019 Grants Received European Union research grant for the ETN MAGICBULLET::RELOADED project KINETO Lab is a member of the European Training Network (ETN) MAGICBULLET, which was launched by the European Union in 2015 as part of the HORIZON 2020 program for research and innovation. More about the consortium you can find on this link. MAGICBULLET::RELOADED is continuation of the project which will be funded from 2019 to 2024 comprising 18 teams of researchers from different European universities, research institutions and companies. Next